(An active ingredient is what makes a drug work.) Keytruda is a biologic medication. A biologic is made from parts of living organisms. It’s available only as a brand-name drug. Keytruda isn’t ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Defensive industries, like healthcare, are more attractive to income investors. That's because companies in this sector are ...

Merck's most important product is Keytruda, a cancer drug that has won approval to treat ... Not everything will make it to market, but I expect many brand-new approvals and label expansions ...

Natalizumab eventually ended up as Tysabri, Biogen’s drug for multiple sclerosis ... in a host of cancer indications under the brand name Keytruda.

Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Keytruda has previously been approved by the Food and Drug Administration as monotherapy and in combination with other therapies for some patients with metastatic or unresectable, recurrent head and ...

Furthermore, Keytruda will lose patent exclusivity in the U.S. in 2028 and then face generic competition ... Its most-recent, brand-new approval of Winrevair, a medicine for pulmonary arterial ...